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Clinical and echocardiographic disease in patients starting end-stage
renal disease therapy. End-stage renal disease (ESRD) patients have a
high cardiovascular mortality rate. Precise estimates of the prevalence,
risk factors and prognosis of different manifestations of cardiac disease are
unavailable. In this study a prospective cohort of 433 ESRD patients was
followed from the start of ESRD therapy for a mean of 41 months.
Baseline clinical assessment and echocardiography were performed on all
patients. The major outcome measure was death while on dialysis therapy.
Clinical manifestations of cardiovascular disease were highly prevalent at
the start of ESRD therapy: 14% had coronary artery disease, 19% angina
pectoris, 31% cardiac failure, 7% dysrhythmia and 8% peripheral vascular
disease. On echocardiography 15% had systolic dysfunction, 32% left
ventricular dilatation and 74% left ventricular hypertrophy. The overall
median survival time was 50 months. Age, diabetes mellitus, cardiac
failure, peripheral vascular disease and systolic dysfunction independently
predicted death in all time frames. Coronary artery disease was associated
with a worse prognosis in patients with cardiac failure at baseline. High
left ventricular cavity volume and mass index were independently associ-
ated with death after two years. The independent associations of the
different echocardiographic abnormalities were: systolic dysfunction—
older age and coronary artery disease; left ventricular dilatation—male
gender, anemia, hypocalcemia and hyperphosphatemia; left ventricular
hypertrophy—older age, female gender, wide arterial pulse pressure, low
blood urea and hypoalbuminemia. We conclude that clinical and echocar-
diographic cardiovascular disease are already present in a very high
proportion of patients starting ESRD therapy and are independent
mortality factors.
Cardiac disease is the major cause of death in dialysis patients,
accounting for 40% of deaths in international registries [1, 2].
When compared to a nonrenal cohort aged 45 to 64 years the
death rate in a dialysis cohort of similar age is 3.5 times higher [3].
The prevalence of clinical manifestations of cardiac disease at the
start of end-stage renal disease (ESRD) therapy is high and these
manifestations independently predict death [4—6].
Echocardiography provides a non-invasive assessment of left
ventricular structure and function. In nonrenal populations echo-
cardiographic left ventricular hypertrophy is an adverse prognos-
tic indicator, independent of age, diabetes, hypertension, hyper-
lipidemia and smoking [7—9]. In a cohort of 90 patients starting
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end-stage renal disease therapy, left ventricular hypertrophy was
shown to adversely and independently influence outcome [10].
Echocardiography also provides information on both left ventric-
ular geometry and left ventricular contractility. The type of left
ventricular geometry, as indicated by the presence of concentric
hypertrophy (in response to pressure overload) or eccentric
hypertrophy (in response to volume overload), may also have
prognostic implications [9]. In the Framingham Heart Study
systolic dysfunction, measured by left ventricular fractional short-
ening, was infrequent, but when present was a more powerful
predictor of mortality then left ventricular hypertrophy [11].
In our previous studies we demonstrated that the prevalence of
severe left ventricular hypertrophy and of systolic failure was high
in dialysis patients [12, 13]. Patients with these two disorders had
a significantly higher mortality than patients with normal echo-
cardiograms [12, 13]. These studies, however, were cross sectional
and included patients established on dialysis for variable periods
of time. In addition, these studies had relatively small numbers of
patients and did not provide multivariate analyses of prognosis.
We now report results from a prospective study in an inception
cohort of 433 patients followed from the initiation of end-stage
renal disease therapy for periods of up to 10 years. In this paper
we report on: (a) the prevalence of clinical and echocardiographic
manifestations of cardiovascular disease at the start of end-stage
renal disease therapy, (b) the prognostic impact of both the
clinical and echocardiographic abnormalities and (c) the associa-
tions of the principal echocardiographic abnormalities.
Methods
Patients
This prospective study was started in the Royal Victoria Hos-
pital, Montreal, Quebec in 1982, in the Health Sciences Centre St.
John's, Newfoundland in 1984, and in the Grace Hospital, St.
John's, Newfoundland in 1985. Patients were eligible for entry to
the study if (a) they had survived for six months and (b) they had
a technically satisfactory echocardiogram within a year of initiat-
ing renal replacement therapy. Patient recruitment at all three
centers finished in June 1991.
Of 518 patients who survived at least six months from the start
of end-stage renal disease therapy a cohort of 433 (83.6% of those
screened) entered the study. Eighty-five patients were excluded
from the study for the following reasons: failure to obtain a
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Age years 51 17
Male/Female % 64.4/35.6
Diabetes mellitus % 26.8
Renal disease %
Glomerulonephritis
Diabetic nephropathy
Nephrosclerosis
Genetic
Other
Unknown 6.7
Hypertension > 10 years % 29.1
Current smoker % 34.9
Systolic blood pressure mm Hg 151 24
Diastolic blood pressure mm Hg 83 24
Serum cholesterol mgldl 205 62
Hemoglobin g/dl 8.4 1.7
Blood urea mgldl 117 153
Serum creatinine mg/dl 10.1 4.6
Serum albumin gIdi 3.4 0.6
Calcium mgldl 8.4 1.2
Inorganic phosphate mg/dl 6.7 2.6
Alkaline phosphatase U/liter 112 74
technically satisfactory echocardiogram within a year of starting
therapy (71 patients); started therapy elsewhere (7 patients);
patients' charts mislaid (5 patients); two patients did not wish to
participate in the study.
Echocardiography was performed at a mean (SD) interval of 3.3
(3.9) months from the time of first dialysis. The mean (SD)
duration of total follow-up was 41.1 (25.7) months. Hemodialysis,
peritoneal dialysis and renal transplantation accounted on aver-
age for 18.8, 12.8 and 9.5 months, respectively, of the total
follow-up.
The clinical and demographic characteristics of the patient
cohort, at the time of study entry, are shown in Table 1. Overall,
the age and proportion of diabetic patients were similar to other
Canadian end-stage renal disease programs [51. Compared to a
typical program in the United States there were more males (64%
vs. 52%) and fewer diabetics (27% vs. 32%) [1]. The study group
was almost entirely Caucasian.
Data collection
At baseline, and at yearly intervals thereafter, a clinical assess-
ment was undertaken to detect risk factors for and the presence of
cardiovascular disease. Baseline and annual echocardiography
was performed using M-mode and 2-dimensional ultrasonogra-
phy. Left ventricular mass index was calculated using the Penn
convention [14]. Left ventricular cavity volume was calculated by
the formula of Pombo, Troy and Russell [15]. Left ventricular
mass and cavity volume were indexed to body surface area,
presented in g/m2 and ml/m2, respectively. Where possible, imag-
ing was carried out when the patient had achieved "dry weight,"
the weight below which hypotension or symptoms such as muscle
cramps occur.
Definitions
The following definitions were used.
Coronaiy artely disease. History of myocardial infarction, coro-
nary artery bypass surgery or percutaneous transluminal angio-
plasty.
Angina pectoris. Precordial chest pain, precipitated by exertion
or stress, relieved by rest or nitrates.
Cardiac failure. Persistent or recurrent dyspnea plus two of the
following: raised jugular venous pressure, bibasalar crackles,
309 pulmonary venous hypertension or interstitial edema on chest
19:9 X-ray [161.
11.1 Peripheral vascular disease. Symptoms of, or surgery for periph-
6.5 eral vascular disease.
17.6 Dysrhythmia. Atrial or ventricular rhythm disorder requiring
therapy.
Arterial pulse pressure. Systolic minus diastolic blood pressure.
Mean arterial pressure. Diastolic blood pressure + 1/3 (arterial
pulse pressure).
LV dilatation. Cavity volume > 90 ml/m2 [15].
LV hypertrophy by mass index. Mass index > 100 g/m2 in
females, mass index > 131 g/m2 in males [17].
Concentric LV hypertrophy. Hypertrophy with normal cavity
volume [18].
Eccentric left ventricular hypertrophy. Hypertrophy with LV dilata-
tion [18].
Systolic dysfunction. Fractional shortening less than or equal to
25% on echocardiography.
Abnormal left ventricle. Any of the following: LV hypertrophy,
LV dilatation or systolic dysfunction.
Cardiac mortality. Death recorded as "myocardial infarction",
"sudden death" or "other cardiac causes."
Analysis
Patient follow-up started with the first dialysis treatment. The
primary outcome measure was death on dialysis therapy. Overall
mortality and death after two years were assessed. We chose the
latter end-point for the following reasons: firstly, because a time
interval between exposure to a risk factor and subsequent mor-
tality might be needed, and secondly, because we felt it likely that
the independent hazards associated with different variables might
not remain constant in time frames as long as those seen in this
study. For the analysis in this report, patients were censored at the
time of renal transplantation or at final follow-up. Cardiac
mortality was a secondary end-point.
Normally distributed continuous variables were compared using
I-tests. Categorical variables were compared using chi-squared
analysis. Stepwise logistic regression analysis was used to assess
the baseline associations, present at the time of first dialysis, of the
different left ventricular abnormalities present on first echocardi-
ography. Univariate survival analysis was carried out using life-
table analysis by the product-limit method. The independent
power of different variables to predict death was assessed using
Cox's regression analysis. The suitability of this model was as-
sessed by split validation, in which data derived from a randomly
generated sample of 2/3 of all patients (test sample) were used to
predict the survival of the remaining 1/3 (validation sample). The
Cox's regression model accurately predicted the actual survival of
validation sample. All statistical tests are two-tailed, with a P value
of less than 0.05 taken to indicate statistical significance. All
logistic regression and survival analyses were carried out with
BMDP software [191.
Table 1. Baseline characteristics in a cohort of 433 ESRD patients
Data refer to mean plus or minus standard deviation.
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Table 2. Prevalence of cardiovascular and echocardiographic
abnormalities at baseline
Variable
Coronary artery disease %
Angina pectoris %
Cardiac failure %
Atrial dysrhythmia %
Ventricular dysrhythmia %
Peripheral vascular disease %
LV mass index g/m2
LV hypertrophy %
Overall
Concentric
Eccentric
LV cavity volume mi/rn2
LV dilatation %
Percentage fractional shortening
Systolic dysfunction %
Data refer to mean plus or minus standard deviation.
Results
Cardiovascular disease at baseline
The prevalence of cardiovascular disease at baseline was high:
14.1% had coronary artery disease, 18.8% angina pectoris, 30.8%
cardiac failure, 7.4% dysrhythmia and 8.4% peripheral vascular
disease. At least one of these entities was present in 43.9% of the
patient cohort at baseline (Table 2).
Echocardiographic abnormalities at baseline: prevalence and
associations
Abnormalities of left ventricular structure and function were
very frequent on baseline echocardiography: 73.9% had left
ventricular hypertrophy, 35.5% had left ventricular dilatation and
14.8% had systolic dysfunction. Using stepwise logistic regression
(Table 3) the associations of the different abnormalities were: left
ventricular hypertrophy—older age, female gender, wide arterial
pulse pressure, low blood urea and hypoalbuminemia; left ven-
tricular dilatation—male gender, anemia, hypocalcemia and hyper-
phosphatemia; systolic dysfunction— older age and coronary artery
disease. Patients without any of these abnormalities tended to be
younger, male, have narrow pulse pressures and to have higher
serum albumin levels (Table 3).
Prognosis: Mortality
The overall median survival for the patient cohort was 50
months (Table 4, Figs. ito 5). The 149 deaths observed during the
study period were attributed to: myocardial infarction (10.1%),
sudden death (25.5%), other cardiac causes (11.4%), other vas-
cular disease (10.7%), infection (14.0%), treatment withdrawal
(12.1%) and other causes (15.4%).
Initial Cox's models were constructed to assess overall mortality
and mortality after two years (Table 4, basic models). In these
models, cardiac failure at baseline was strongly predictive of
overall mortality and mortality after two years. Coronary artery
disease and angina were without impact. The conclusions were
identical when both variables were combined, or either angina or
coronary artery disease was excluded from the analysis.
The impact of coronary artery disease may be via the develop-
ment of cardiac failure. Patients were divided into four groups:
those free of coronary artery disease and cardiac failure at
Abnormality Associations OR P
LV hypertrophy Age years
Male gender
Arterial pulse pressure mm Hg
Blood urea rng/dl
Serum albumin g/liter
Constant
1.04
0.33
1.02
0.999
0.65
1.43
<i0
<iO
0.004
0.052
0.060
0.366
LV dilatation Male gender
Hemoglobin g/dl
Calcium mg/dl
Inorganic phosphate rng/dl
Constant
1.87
0.90
0.79
1.09
3.35
0.007
0.096
0.001
0.024
<iO
Systolic dysfunction Age years
Coronary artery disease
Constant
1.02
3.13
0.05
0.055
0.018
0.994
Abnormal left Age years 1.02 <iO
ventriclec Male gender
Arterial pulse pressure mm Hg
Serum albumin g/dl
Constant
0.38
1.02
0.51
4.52
0.005
0.012
0.005
0.964
a The covariates included in each analysis were age, gender, diabetes
mellitus, coronary artery disease, angina pectoris, hypertension > 10
years, arterial pulse pressure, mean arterial blood presssure, hemoglobin,
blood urea, serum creatinine, inorganic phosphate, calcium, alkaline
phosphatase and serum albumin levels. The global P value was <0.001 for
each analysis.bThe blood pressures and laboratory values are those taken on the day
of first dialysis. LV denotes left ventricular.
Any of the following: LV hypertrophy, LV dilatation or systolic
dysfunction.
baseline (Group I); coronary artery disease without cardiac failure
(Group II); cardiac failure without coronary artery disease
(Group III) and both coronary artery disease and cardiac failure
(Group IV). In proportional hazards models (adjusted for age,
diabetes and baseline serum albumin levels) in which Group I was
the reference category, the relative risk of death was 1.09 (P =
0.814) for Group II, 1.78 (P = 0.004) for Group III and 2.52 (P =
0.004), suggesting that coronary artery disease effects the progno-
sis of those with cardiac failure at baseline.
When added individually to the basic Cox's model, peripheral
vascular disease, left ventricular fractional shortening and systolic
dysfunction were associated with all-cause mortality, indepen-
dently of age, diabetes, coronary artery disease, angina pectoris,
cardiac failure and baseline serum albumin. For patients who
survived more than two years, peripheral vascular disease, left
ventricular mass index, eccentric as opposed to concentric left
ventricular hypertrophy, left ventricular cavity volume, left ven-
tricular dilatation, fractional shortening and systolic dysfunction
were all associated with late mortality. Systolic dysfunction, left
ventricular cavity volume and left ventricular mass were all
directly correlated with each other. When these three variables
were added together to the basic Cox's model, only left ventricular
cavity volume retained its statistical significance in the prediction
of late mortality. Figures 1 to 5 show the survival curves, after
covariate adjustment using the Cox's model, for patients with and
without coronary artery disease, cardiac failure, systolic dysfunc-
tion, average left ventricular mass index and left ventricular
Table 3. Independent associations, using stepwise logistic regression,a
of (I) left ventricular hypertrophy (N = 283/403), (II) left ventricular
dilatation (N = 144/406), (III) systolic dysfunction (N = 64/433) and(IV) abnormal left ventricle (N = 342/4O5)t
14.1
18.8
30.8
6.0
1.4
8.4
158 48
73.9
44.3
29.6
82 37
35.5
33.9 8.2
14.8
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dilatation. It can be appreciated that the last two variables had
little impact on survival before two years.
When cardiac mortality was chosen as end-point the conclu-
sions were virtually identical to those for all-cause mortality:
cardiac failure, peripheral vascular disease, left ventricular frac-
tional shortening, systolic dysfunction and, in addition, left ven-
tricular cavity volume, were associated with cardiac mortality in all
time frames, whereas left ventricular mass index was indepen-
dently associated with death after two years (data not shown).
Discussion
Clinical cardiovascular disease: Prevalence and prognosis
In this cohort of dialysis patients the prevalence of clinically
manifested cardiovascular disease was high at the start of renal
replacement therapy. A history of cardiac failure, in particular,
was an independent predictor of mortality. Similar findings have
been reported previously, from both retrospective [4, 6] and
prospective studies [51. In this study the presence of coronary
artery disease, angina pectoris or atrial dysrhythmia had little
impact on subsequent mortality. These findings may reflect the
six-month survival needed as a study entry criterion. Data accrued
in one of the centres used for this study over a 10 year period
suggest that both ischemic heart disease and dysrhythniias are
powerful predictors of mortality within the first six months of
Table 4. Prognosis: Adjusteda relative risk of overall mortality, and late
mortality (> 2 years), using Cox's regression
No cardiac failure
Basic model: Overall mortality Late mortality
# Deaths/total at risk 145/420 70/290
Variable RR P RR P
Age (per year) 1.031 <iO 1.035 0.0009
Diabetes mellitus 1.952 0.0002 1.915 0.009
Coronary artery disease 1.022 0.931 1.156 0.697
Angina pectoris 1.218 0.409 1.034 0.923
Cardiac failure 1.846 0.006 1.790 0.015
Serum albumin per g/di 0.744 0.079 0.674 0.046
Global P value — <i0 — <iO
Covariates added'
Atrial dysrhythmia 1.403 0.391 1.390 0.353
Peripheral vascular 1.825 0.014 2.718 0.004
disease
LV mass per g/m2 1.003 0.107 1.009 0.0007
LV hypertrophy 0.853 0.555 1.779 0.214
Eccentric vs Concentric 1.295 0.202 1.730 0.047
LVH
LV cavity volume per
mi/rn2
1.009 0.071 1.011 <i0
LV dilatation 1.375 0.093 1.858 0.019
LV fractional shortening 0.978 0.047 0.961 0.013
per %
LV systolic dysfunction 1.597 0.027 2.034 0.015
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Fig. 2. Estimated survival, using Cox's regression analysis (using age, diabe-
tes, coronary artery disease, angina pectoris, and serum albumin as covari-
ates) for patients with and without cardiac failure at baseline.
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Fig. 3. Estimated survival, using Cox's regression analysis (using age, diabe-
tes, coronary artery disease, angina pectoris, cardiac failure and serum
albumin as covariates) for patients with and without systolic dysfunction at
baseline.
Coronary artery disease
Adjusted for age, diabetes, coronary artery disease, angina pectoris,
cardiac failure, serum albumin on starting dialysisbAdded one at time to basic model
0.8
0.6
0.4
0.2
0
0 6 12 18 24 30 36 42 48 54 60 66 72
Fig. 1. Estimated survival, using Cox's regression analysis (using age, diabe-
tes, angina pectoris, cardiac failure and serum albumin as covariates) for
patients with and without coronary artery disease at baseline.
0 6 12 18 24 30 36 42 48 54 60 66 72
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chronic dialysis therapy [20]. A recent retrospective study, involv-
ing a large number of patients followed from the initiation of
dialysis therapy, suggests that coronaiy artery disease is a risk
factor for subsequent mortality [6]. Subgroup analysis of this study
suggested that the presence of ischemic heart disease appeared to
worsen the prognosis of patients with cardiac failure at baseline.
The lack of independent impact of coronary artery disease was
also seen in the study of Hutchinson, Thomas and Mac Gibbon in
which the adverse effect of myocardial infarction and angina
pectoris seen on univariate analysis was lost in multivariate
models that included age, diabetes mellitus and cardiac failure as
covariates [4]. It is likely that cardiac failure and ischemic heart
disease are highly correlated with one another. A more appropri-
ate design might be to gauge the impact of de novo ischemic heart
disease on prognosis in patients free of overt cardiac disease at
baseline. Our study also suggests that peripheral vascular disease
is a risk factor for mortality in dialysis patients, independently of
clinically manifested cardiac disease, as has been observed in
other dialysis populations [6].
Echocardiographic abnor,nalities: Prevalence and prognosis
In this study, echocardiographic abnormalities were the rule on
baseline echocardiography: only 63 of 409 (15.5%) patients were
free from left ventricular dilatation, hypertrophy and systolic
dysfunction at baseline. Other investigators have reported that left
ventricular dilatation [211, hypertrophy [22] and systolic dysfunc-
tion [23] are common in dialysis patients.
Abnormalities present on baseline echocardiography were in-
dependent predictors of both overall and cardiac mortality in this
study. The association with overall mortality is consistent with the
limited literature currently available to us [10, 12, 13]. Abnormal-
ities of cardiac contractility were associated with mortality in all
time frames. The adverse effects of left ventricular hypertrophy
and dilatation were more readily apparent among patients who
had survived over two years. The effects on mortality suggest that
a period of risk exposure predates subsequent mortality, offering
the possibility that effects on mortality may be remediable. This
parallels the situation in non-uremic hypertensive patients, in
which the prognostic impact of left ventricular hypertrophy is
minimal in the first five years of follow-up [9]. Clearly, more
epidemiological studies and clinical trials are warranted. In that it
further stratifies risk, these data suggest that baseline echocardi-
ography is indicated in patients starting dialysis therapy.
Echocardiographic abnormalities: Associations
The current study was designed to identify potential interven-
tions that might be used to treat and prevent cardiac disease in
chronic uremia. A more appropriate research design to identify
potentially reversible risk factors might be a nested case-control
study in which patients without the condition under study are
followed prospectively until they develop this problem. The
prevalence of clinical and echocardiographic disease is already
very high starting renal replacement therapy, suggesting that these
studies should be performed in the pre-uremic phase. In this
paper we report associations between echocardiographic abnor-
malities and potential risk factors present at the initiation of renal
replacement therapy. Older age, gender, coronary artery disease,
wide arterial pulse pressure, anemia, low blood urea, hypoalbu-
minemia, hypocalcemia and hyperphosphatemia were identified
as associations of the different echocardiographic abnormalities
(Table 3). Other studies have implicated age as a risk factor for
echocardiographic abnormalities in dialysis patients [23—26]. Gen-
der has not been consistently associated with echocardiographic
abnormalities in dialysis patients. These analyses did not suggest
an independent role for diabetes mellitus, although other re-
searchers have suggested that left ventricular hypertrophy and
diastolic dysfunction may be early manifestations of cardiomyop-
athy [27, 28]. The association between coronary artery disease and
systolic dysfunction is to be expected. What is more surprising is
the lack of association between coronary artery disease and the
other types of abnormality. Coronary artery disease and angina
0.8
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Time, months
Fig. 4. Predicted survival, using Cox's regression analysis (using age, diabe-
tes, coronaty artemy disease, angina pectoris, cardiac failure and serum
albumin as covariates) for patients with left ventricular mass index above and
below the sex-adjusted mean.
Normal cavity volume
0.4
0.2
0 6 12 18 24 30 36 42 48 54 60 66 72
0
0 6 12 18 24 30 36 42 48 54 60 66 72
Time, months
Fig. S. Estimated survival, using Cox's regression analysis (using age, diabe-
tes, coronamy arte,y disease, angina pectoris, cardiac failure and serum
albumin as covariates) for patients with and without left ventricular dilatation
at baseline.
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pectoris were defined clinically in this study. Coronary angiogra-
phy was not performed routinely. It is known that ischemic heart
disease can occur in dialysis patients without anatomical coronary
artery stenosis [29]. It is also known that there is a large burden of
silent coronary artery disease in this population [30]. The poor
correlation between ischemic heart disease and baseline echocar-
diographic abnormalities seen in this study may partly reflect
these divergent effects. We did not systematically examine arte-
riovenous connection flow-rates, although such abnormalities are
likely to be associated with left ventricular abnormalities in
dialysis patients [21]. The association between left ventricular
hypertrophy and arterial pulse pressure is perhaps explicable on
this basis. As was seen in this study, anemia is very likely to have
a contributory role in the echocardiographic abnormalities seen in
dialysis patients [31—35]. The associations with hypocalcemia and
hyperphosphatemia are consistent with the hypothesis that hyper-
parathyroidism may play a role in uremic cardiomyopathy [21, 24,
25]. Because baseline data on parathyroid hormone levels were
incomplete, these hypotheses must remain speculative.
The associations between low blood urea, hypoalbuminemia
and echocardiographic abnormalities have not been described
previously. It is tempting to speculate that both are nutritional
indices, and as such, may mark for more prolonged uremia in the
predialysis phase. The current study suggests the possibility that
the adverse effect of hypoalbuminemia [6, 36—39] may be exerted,
at least in part, through the induction of cardiac abnormalities.
This study failed to document an association between a history
of chronic hypertension and any of the echocardiographic abnor-
malities studied, although a wide pulse pressure appeared to be
related to the presence of left ventricular hypertrophy. In general,
the role of hypertension in the pathogenesis of uremic cardiom-
yopathy has been difficult to elucidate, although recent studies
suggest a role [26, 40].
Conclusions
We conclude that both clinical and echocardiographic disease
occur frequently in chronic uremia. Of the clinical abnormalities,
cardiac failure appears to the most important adverse prognostic
indicator. Echocardiographically-identified left ventricular sys-
tolic dysfunction, dilatation and hypertrophy are also independent
predictors of mortality.
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